Evidence map›Paper›PMID 42394705›Full record

ArticleFrontiers in oncology2026

Risk stratification for adjuvant radiotherapy in pathologic T3N0 rectal cancer using a DeepSurv-based survival model.

Yunxia Huang, Yanzong Lin, Qingyang Zhuang, Xinyuan Wu, Qiping Fan, Junxin Wu

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Yunxia HuangDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Yanzong LinDepartment of General Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China.
Qingyang ZhuangDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Xinyuan WuDepartment of Urology, The First Clinical Medical College of Southern Medical University, Guangzhou, China.
Qiping FanDepartment of Public Health Sciences, Clemson University, Clemson, SC, United States.
Junxin WuDepartment of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The role of adjuvant radiotherapy in patients with pathologic T3N0 rectal cancer remains controversial. Although overall prognosis is favorable, marked heterogeneity exists, and reliable tools to identify patients who may derive meaningful benefit from postoperative radiotherapy are lacking. This study aimed to develop and validate a deep learning-based prognostic model to support individualized radiotherapy decision-making in this population. Methods: We included 1,411 patients with pT3N0 rectal adenocarcinoma from the Surveillance, Epidemiology, and End Results (SEER) database for model development and internal validation. An independent real-world cohort of 118 patients was used for external validation. A DeepSurv-based survival model was constructed using clinicopathological variables to predict cancer-specific survival (CSS). Model performance was evaluated using time-dependent area under the receiver operating characteristic curve (AUC). SHapley Additive exPlanations (SHAP) were applied to improve model interpretability. Subgroup analyses were conducted to assess the survival impact of adjuvant radiotherapy across model-defined risk strata. Results: The DeepSurv model showed good discrimination, with 3-, 5-, and 10-year AUCs of 0.749, 0.739, and 0.769 in the training set and 0.819, 0.753, and 0.711 in the external validation cohort, respectively. Using the prespecified cutoff, risk stratification revealed differential survival patterns according to adjuvant radiotherapy status. Specifically, adjuvant radiotherapy was associated with improved survival in high-risk patients in both the SEER cohort (log-rank P < 0.001) and the external cohort (log-rank P = 0.032), but not in low-risk patients. Building on our prior Cox-based approach, DeepSurv captured nonlinear relationships and interactions to better individualize radiotherapy benefit. SHAP analysis identified carcinoembryonic antigen status as the most influential predictor. Conclusions: This DeepSurv-based prognostic model effectively stratifies patients with pT3N0 rectal cancer and may help identify individuals who could potentially benefit from adjuvant radiotherapy. A risk-adapted postoperative treatment strategy may support individualized decision-making by prioritizing radiotherapy for high-risk patients while avoiding potential overtreatment in low-risk individuals.

Indexed as

adjuvant radiotherapyDeepSurvpT3N0 rectal cancerrisk stratificationsurvival model

Identifiers

PMID42394705
PMCPMC13324130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.